The transcript for Amgen Inc.'s first quarter 2006 financial results call presents several key points that could impact the stock price in the short term:

### Positive Factors
- **Strong Revenue and EPS Growth**: Total revenues and adjusted EPS saw significant increases, with revenues up 14% and adjusted EPS up 26% compared to the prior year[5|.
- **Robust Product Performance**: Most of Amgen's products, including Aranesp, Neulasta, and Sensipar, showed strong sales growth. Aranesp sales increased 24%, Neulasta and NEUPOGEN sales rose 13%, and Sensipar sales increased 126%[5|.
- **Pipeline Advancements**: The company highlighted significant progress in its pipeline, including the approval of every-three-week dosing for Aranesp, the BLA submission for panitumumab, and ongoing trials for denosumab and other compounds[5|.
- **Acquisition and Strategic Moves**: The acquisition of Abgenix and the completion of a $5 billion convertible debt issuance with concurrent share repurchases indicate strategic strength and financial flexibility[5].

### Potential Challenges
- **Reimbursement and Competitive Environment**: The company faces challenges in the reimbursement environment, particularly with the Competitive Acquisition Program (CAP) and the impact of Part D enrollment issues on Enbrel sales. Additionally, increased competition from products like REMICADE and potential biosimilars in the EU could pose future risks[5|.
- **Litigation**: The ongoing litigation with Roche over peg-EPO could introduce uncertainty, although Amgen expressed confidence in its patent portfolio[5|.
- **R&D Expenses**: Amgen's plan to increase R&D expenses by 30-40% could impact short-term profitability[5!.

Given these factors, the overall sentiment is positive due to strong financial performance, robust product sales, and significant pipeline advancements. However, there are some potential challenges related to reimbursement and competition.

### Conclusion
The stock is likely to see a positive impact in the short term due to the strong financial results, pipeline progress, and strategic moves, despite some potential headwinds.

**Rating: 1**